Quantcast

Latest Prostate cancer Stories

2014-09-11 12:27:33

SANTA MONICA, Calif., Sept. 11, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) has awarded 27 new Young Investigator Awards selected from 16 countries to advance new drug discovery, immunotherapy, nutritional sciences, and diagnostics for precision medicine. Young Investigator (YI) Awards stand out among PCF's prestigious research programs, and serve to jumpstart the research careers of recent MDs and PhDs. These 3-year awards are game-changing investments that...

2014-09-11 08:28:17

Hosting an educational symposium highlighting treatment advances using the Company's high-dose rate electronic brachytherapy system NASHUA, N.H. and SAN FRANCISCO, Sept. 11, 2014 /PRNewswire/ -- (Booth #1938) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company's latest technological advances and present updates on clinical data and patient...

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-09-08 12:28:32

OWINGS MILLS, Md., Sept. 8, 2014 /PRNewswire-USNewswire/ -- Chesapeake Urology, the largest urology practice in the mid-Atlantic and one of the leading urology groups in the nation, is sponsoring its 8(th) Annual ZERO Prostate Cancer Challenge/Baltimore (ZPCC) on Sunday, September 14, 2014 during Prostate Cancer Awareness Month. The event will be held at Towson University's Johnny Unitas Stadium in Towson, MD. Dr. Sanford J. Siegel, President and CEO of Chesapeake Urology,...

2014-09-08 08:31:12

Patients also report significant impact on mood and career WASHINGTON, Sept. 8, 2014 /PRNewswire/ -- A recent survey conducted by ZERO - The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs) that support them. The majority (64 percent) of patients surveyed report that their prostate cancer diagnosis has a moderate to severe impact on their social and emotional wellbeing....

2014-09-08 08:31:01

BETHESDA, Md., Sept. 8, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at 2:05 pm on Tuesday, September 9, 2014, in the Holmes I Salon at the Palace Hotel in New York as part of the Rodman & Renshaw 16(th) Annual Global Investment Conference. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO...

2014-09-05 23:00:54

Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone. Data Presented at International Liver Cancer Association Conference. MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with...

2014-09-04 12:26:30

Dr. Drew Pinsky's personal battle with prostate cancer inspires him to join forces with PCF SANTA MONICA, Calif., Sept. 4, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) announced that Drew Pinsky, MD has been elected to the Board of Directors. "Drew has valuable experience in internal and addiction medicine," said Jonathan W. Simons, MD, president and CEO of PCF. "As one of approximately 16 million prostate cancer survivors worldwide, Drew brings personal...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.